Effect of receptor blockers on brain natriuretic peptide and C-type natriuretic peptide caused anxiolytic state in rats

被引:41
|
作者
Biro, E
Toth, G
Telegdy, G
机构
[1] ALBERT SZENT GYORGYI MED UNIV,DEPT PATHOPHYSIOL,H-6701 SZEGED,HUNGARY
[2] ALBERT SZENT GYORGYI MED UNIV,DEPT MED CHEM,H-6701 SZEGED,HUNGARY
基金
匈牙利科学研究基金会;
关键词
D O I
10.1016/S0143-4179(96)90056-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Effect of different doses of centrally administered brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) were examined in rats with respect to anxiolytic properties in an elevated plus-maze model. BNP in doses of 100, 200 and 400 ng, and CNP in doses of 100 and 200 ng abolished the normal preference for the closed arms of the maze, and increased the percentage time spent in the open arms; this is consistent with an 'anxiolytic-like' effect. Doses of 50 and 1000 ng BNP, and of 25, 50, 400 and 1000 ng CNP produced no behavioural effects in the elevated plus-maze model. Pretreatment with an alpha-adrenoreceptor antagonist or a muscarinergic cholinergic blocker, antagonized the effect of 200 ng BNP in the elevated plus-maze test. The 'anxiolytic-like' effects of a BNP were not modulated by a dopaminergic blocker, an alpha-adrenoreceptor antagonist, a GABA receptor antagonist, a 5-HT receptor antagonist or an opiate antagonist. The 'anxiolytic-like' effect of CNP was prevented by a dopamine receptor antagonist, or an alpha- or beta-adrenoreceptor blocker but not by a muscarinergic cholinergic blocker, a GABA receptor, a 5-HT receptor antagonist or an opiate receptor antagonist. These results suggest that multiple neurotransmitter system activation might be responsible for the BNP and CNP-induced 'anxiolytic-like' activity.
引用
收藏
页码:59 / 65
页数:7
相关论文
共 50 条
  • [31] C-type natriuretic peptide in prostate cancer
    Nielsen, Soeren Junge
    Iversen, Peter
    Rehfeld, Jens F.
    Jensen, Helle Lone
    Goetze, Jens Peter
    APMIS, 2009, 117 (01) : 60 - 67
  • [32] C-type natriuretic peptide and heart failure
    Del Ry, Silvia
    Passino, Claudio
    Emdin, Michele
    Giannessi, Daniela
    PHARMACOLOGICAL RESEARCH, 2006, 54 (05) : 326 - 333
  • [33] Regulation of C-type natriuretic peptide expression
    Sellitti, Donald F.
    Koles, Nancy
    Mendonca, Maria C.
    PEPTIDES, 2011, 32 (09) : 1964 - 1971
  • [34] C-Type Natriuretic Peptide and Cardiac Fibrosis
    Richards, A. Mark
    HYPERTENSION, 2011, 57 (02) : 154 - 155
  • [35] C-type natriuretic peptide in childhood obesity
    Cabiati, Manuela
    Sgalippa, Agnese
    Federico, Giovanni
    Del Ry, Silvia
    PEPTIDES, 2021, 145
  • [36] C-type natriuretic peptide is produced by the kidneys
    Kalra, PR
    Clague, JR
    Bolger, A
    Sharma, R
    Anker, SD
    Poole-Wilson, PA
    Coats, AJ
    Struthers, AD
    EUROPEAN HEART JOURNAL, 2004, 25 : 651 - 651
  • [37] C-TYPE NATRIURETIC PEPTIDE IS A POTENT VENODILATOR
    WEI, CM
    AARHUS, LL
    MILLER, VM
    BURNETT, JC
    CIRCULATION, 1992, 86 (04) : 219 - 219
  • [38] HUMAN C-TYPE NATRIURETIC PEPTIDE (CNP) - STRUCTURE OF THE GENE AND IDENTIFICATION OF THE PEPTIDE IN BRAIN
    OGAWA, Y
    NAKAO, K
    NAKAGAWA, O
    KOMATSU, Y
    MUKOYAMA, M
    HOSODA, K
    SUGA, S
    ARAI, H
    SHIRAKAMI, G
    KISHIMOTO, I
    HAMA, N
    IMURA, H
    HYPERTENSION, 1991, 18 (03) : 392 - 393
  • [39] EFFECT OF C-TYPE NATRIURETIC PEPTIDE ON JUXTAMEDULLARY AFFERENT ARTERIOLE
    AMIN, JP
    CARRETERO, OA
    ITO, S
    HYPERTENSION, 1995, 26 (03) : 572 - 572
  • [40] Characterization of C-type natriuretic peptide chronotropic effect.
    Beaulieu, P
    Cardinal, R
    Francoeur, F
    Tremblay, J
    Lambert, C
    CIRCULATION, 1996, 94 (08) : 4182 - 4182